Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + tacrolimus + mycophenolate mofetil + granulocyte colony-stimulating factor
- Development stage
- Unknown
- Lead developer
- Medical College of Wisconsin
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a multi-agent Graft-versus-Host Disease (GVHD) prophylaxis regimen evaluated by the Medical College of Wisconsin in the Phase II BMT CTN 0603 trial for patients with leukemia or lymphoma undergoing haploidentical bone marrow transplantation. The regimen consists of high-dose post-transplant cyclophosphamide (PTCy) administered on days 3 and 4, followed by tacrolimus, mycophenolate mofetil (MMF), and granulocyte colony-stimulating factor (G-CSF) starting on day 5. PTCy works by selectively eliminating alloreactive T cells while preserving regulatory T cells and hematopoietic stem cells. Tacrolimus and MMF provide additional immunosuppression by inhibiting calcineurin and inosine monophosphate dehydrogenase, respectively, while G-CSF is used to support myeloid recovery and neutrophil engraftment.
- Other names
- PTCy + Tac + MMF + G-CSFPost-transplant cyclophosphamide-based GVHD prophylaxisGVHD prophylaxis-Medical College of Wisconsin-leukemia-lymphoma
02
Targets
CN (Calcineurin)CSF3R (Granulocyte colony-stimulating factor receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)DNA
Beyond the preview
Go deeper on cyclophosphamide + tacrolimus + mycophenolate mofetil + granulocyte colony-stimulating factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + tacrolimus + mycophenolate mofetil + granulocyte colony-stimulating factor.